1022091-49-1

Basic information

• Product Name: 5,7-Difluoro-6-bromoquinoline
• Synonyms: 5,7-Difluoro-6-bromoquinoline;6-Bromo-5,7-difluoroquinoline
• CAS NO: 1022091-49-1
• Molecular Formula: C9H4BrF2N
• Molecular Weight: 244.0355664
• EINECS: 1312995-182-4
• Product Categories: Building Blocks;C8 to C10;Chemical Synthesis;Fluorinated Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles;Quinolines;Building Blocks/Intermediates
• Mol File: 1022091-49-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 87-92℃
• Boiling Point: 288℃
• Flash Point: 128℃
• Appearance: /
• Density: 1.726
• Storage Temp.: 2-8°C
• PKA: 2.05±0.29(Predicted)
• CAS DataBase Reference: 5,7-Difluoro-6-bromoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-Difluoro-6-bromoquinoline(1022091-49-1)
• EPA Substance Registry System: 5,7-Difluoro-6-bromoquinoline(1022091-49-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• RIDADR: UN 3335
• WGK Germany: 1
• Hazardous Substances Data: 1022091-49-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 203302-95-8 4-bromo-3,5-difluorophenylamine 
• 56-81-5 glycerol 
• 372-39-4 3,5-difluoroaniline 

Downstream Products

• 1185767-02-5 5,7-difluoroquinoline-6-carbaldehyde 

Relevant articles and documents

Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization

c-Met/HGF signaling pathway plays an important role in cancer progression, and it was considered to be related to poor prognosis and drug resistance. Based on metabolite profiling of (S)-7-fluoro-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyrazin

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

HETEROCYCLIC KINASE MODULATORS

The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.